Nucleic acid of recombination expression vector encoding soluble forms of CD83, host cells transformed/transfected therewith and pharmaceutical compositions containing same
Number of patents in Portfolio can not be more than 2000
United States of America Patent
Stats
-
Aug 11, 2015
Grant Date -
Jun 10, 2004
app pub date -
Mar 6, 2003
filing date -
Dec 4, 2002
priority date (Note) -
In Force
status (Latency Note)
Importance
Abstract
The present invention provides methods of using soluble forms of CD83 and nucleic acids encoding them for the treatment or prevention of diseases caused by the dysfunction or undesired function of a cellular immune response involving T cells. The invention moreover provides soluble CD83 proteins, specifically suited for said purpose, nucleic acids and vectors encoding said CD83 proteins, cells transformed/transfected with the nucleic acids or vectors, methods for producing said CD83 proteins, pharmaceutical compositions containing said CD83 proteins, nucleic acids or vectors, and antibodies against said soluble CD83 proteins and assay methods and kits comprising said antibodies.
First Claim
Family
International Classification(s)
- [Classification Symbol]
- [Patents Count]
Cited Art Landscape
Patent Citation Ranking
Advertisement
Advertisement
Advertisement
Recipient Email Address
Recipient Email Address
Comment
Recipient Email Address
Add to Portfolio(s)
To add this patent to one, or more, of your portfolios, simply click the add button.
This Patent is in these Portfolios:
Add to additional portfolios:
Last Refreshed On:
Changes done successfully